Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02765945 · ClinicalTrials.gov registry record · NA
Exercise as an Modulator of Immunological Risk Factors for Osteoporosis
A NA study, sponsored by East Tennessee State University.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
NCT02765945: Completed NA study, sponsored by East Tennessee State University.
NCT02765945 is a NA study that has completed, run by East Tennessee State University. The registered enrollment target is 43 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02765945, a NA study, has completed, sponsored by East Tennessee State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
Study Summary
This is the second phase of a study designed to determine the immunological effects of long-term exercise on risk factors for ischemic heart disease (phase 1) and osteoporosis (phase 2). The results indicate that six months of moderate intensity exercise reduces bone resorption and increases the secretion of anti-osteoclastogenic cytokines by peripheral blood mononuclear cells.
Interventions
- OTHER Supervised exercise program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 1996-12 |
| Est. Completion | 1998-04 |
| Phase | NA |
What the finished NCT02765945 record still lists
NCT02765945 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Supervised exercise program is the first listed.
NCT02765945 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02765945 about?
NCT02765945 is a clinical study titled "Exercise as an Modulator of Immunological Risk Factors for Osteoporosis". This is the second phase of a study designed to determine the immunological effects of long-term exercise on risk factors for ischemic heart disease (phase 1) and osteoporosis (phase 2). The results indicate that six months of moderate intensity exercise reduces bone resorption and increases the sec...
What is the current status of trial NCT02765945?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 1996-12. Estimated completion is 1998-04.
What interventions are being tested in trial NCT02765945?
The interventions under investigation include: Supervised exercise program (OTHER).
Who is sponsoring clinical trial NCT02765945?
This trial is sponsored by East Tennessee State University, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02765945's enrollment target sits among peer trials
43 1435th of 2000 higher than 565 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia